Articles related to PEDIATRIC ENDOCRINOLOGY

The FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding a device previously limited to adults and supporting caregiver-supervised home glucose monitoring.

A JCEM clinical guidance article outlines a two-criterion diagnostic standard for adolescent PCOS, requiring both persistent hyperandrogenism and menstrual irregularity, and frames adolescence as the critical window for metabolic and psychosocial risk stratification.

The FDA approved inhaled insulin (Afrezza) for pediatric patients aged 6 and older with type 1 or type 2 diabetes, based on phase 3 trial data and long-term safety evidence from manufacturer-sponsored studies.

Pediatric patients who started automated insulin delivery within 6 months of type 1 diabetes diagnosis had a median HbA1c of 7.1% at 24 months versus 9.8% in non-users in a US multicenter retrospective cohort.

Children labeled metabolically healthy at obesity treatment initiation reached an 18-fold higher type 2 diabetes incidence by age 30 than general population peers in a 42,911-patient Swedish cohort.

“Families and health care professionals now have the option to consider a once-weekly growth hormone as treatment with 313 injection free days per year for their children 2.5 years and older with ISS, NS, and born SGA,” said Dr Aristides Maniatis, Founder, Rocky Mountain Pediatric Endocrinology.